BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. ELTX “Elicio Therapeutics” or “Elicio”))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced promising preliminary relapse-free survival (RFS) data from the ongoing Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002.…Read More
Elicio Therapeutics Presents Updated Preliminary Data Including Promising RelapseFree Survival Data from the Phase 1 Study of ELI002 at AACR Special Conference Pancreatic Cancer Elicio Therapeutics NASDAQELTX
